The metabolism of Methylphenidate can be decreased when combined with Fluoxetine. The serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Methylphenidate. The risk or severity of adverse effects can be increased when Pipotiazine is combined with Methylphenidate. Cimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The metabolism of Methylphenidate can be decreased when combined with Venlafaxine. Methylphenidate may decrease the antihypertensive activities of Niguldipine. Methylphenidate may decrease the antihypertensive activities of Lercanidipine. The serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b. The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate. Dexlansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Methylphenidate may decrease the antihypertensive activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Levodopa. Bismuth Subcitrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Tianeptine. Pheniprazine may increase the hypertensive activities of Methylphenidate. Magaldrate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine. Aluminium can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Ritanserin is combined with Methylphenidate. Rasagiline may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Melperone is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Aliskiren. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Bromocriptine. The risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Perindopril. The risk or severity of adverse effects can be increased when Triflupromazine is combined with Methylphenidate. Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Methylphenidate may decrease the antihypertensive activities of Penbutolol. The serum concentration of Warfarin can be increased when it is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Imidapril. Methylphenidate may decrease the antihypertensive activities of Minoxidil. Methylphenidate may decrease the antihypertensive activities of Ticrynafen. Famotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Methylphenidate may decrease the antihypertensive activities of Bethanidine. The risk or severity of adverse effects can be increased when Lithium is combined with Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Lorcaserin. Mebanazine may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Zotepine is combined with Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Delavirdine. Methylphenidate may decrease the antihypertensive activities of Selexipag. The risk or severity of adverse effects can be increased when Paliperidone is combined with Methylphenidate. Benmoxin may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Rotigotine. The serum concentration of Metoprolol can be increased when it is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Bisoprolol. Methylphenidate may decrease the antihypertensive activities of Telmisartan. Methylphenidate may decrease the antihypertensive activities of Tibolone. Methylphenidate may decrease the antihypertensive activities of Spirapril. The risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Pentolinium. The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Flupentixol is combined with Methylphenidate. Aluminum hydroxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Lansoprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate. Almasilate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amitriptyline. The metabolism of Methylphenidate can be decreased when combined with Amiodarone. Methylphenidate may decrease the antihypertensive activities of Rilmenidine. Methylphenidate may decrease the antihypertensive activities of Tolazoline. Methylphenidate may decrease the antihypertensive activities of Debrisoquin. The metabolism of Methylphenidate can be decreased when combined with Quinine. Methylphenidate may decrease the antihypertensive activities of Enalapril. Methylphenidate may decrease the antihypertensive activities of Propranolol. Methylphenidate may increase the hypertensive activities of Desflurane. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Amantadine. Methylphenidate may decrease the antihypertensive activities of Deserpidine. The risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Chlorthalidone. Harmaline may increase the hypertensive activities of Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Mirabegron. The risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Atenolol. Methylphenidate may decrease the antihypertensive activities of Trandolapril. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Pramipexole. The risk or severity of adverse effects can be increased when Pimozide is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Fencamfamine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Cyclopenthiazide. The risk or severity of adverse effects can be increased when Molindone is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Pargyline. Methylphenidate may decrease the antihypertensive activities of Chlorothiazide. Methylphenidate may decrease the antihypertensive activities of Terlipressin. The serum concentration of Phenobarbital can be increased when it is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Mibefradil. The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Guanfacine. Hydracarbazine may increase the hypertensive activities of Methylphenidate. The risk or severity of adverse effects can be increased when Amisulpride is combined with Methylphenidate. Pirlindole may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Hydralazine. The metabolism of Methylphenidate can be decreased when combined with Cinacalcet. Tranylcypromine may increase the hypertensive activities of Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Diphenhydramine. Methylphenidate may decrease the antihypertensive activities of Unoprostone. Methylphenidate may decrease the antihypertensive activities of Bupranolol. The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Nitroprusside. Methylphenidate may decrease the antihypertensive activities of Methyldopa. The risk or severity of adverse effects can be increased when Remoxipride is combined with Methylphenidate. The metabolism of Methylphenidate can be decreased when combined with Dronedarone. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine. The metabolism of Methylphenidate can be decreased when combined with Fluvoxamine. Methylphenidate may decrease the antihypertensive activities of Zofenopril. Methylphenidate may decrease the antihypertensive activities of Vincamine. Methylphenidate may decrease the antihypertensive activities of Mecamylamine. Methylphenidate may decrease the antihypertensive activities of Latanoprost. The metabolism of Methylphenidate can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Benperidol is combined with Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Quinapril. Methylphenidate may decrease the antihypertensive activities of Felodipine. Methylphenidate may decrease the antihypertensive activities of Bendroflumethiazide. The metabolism of Methylphenidate can be decreased when combined with Cocaine. Minaprine may increase the hypertensive activities of Methylphenidate. Methylphenidate may decrease the antihypertensive activities of Nitrendipine. Methylphenidate may decrease the antihypertensive activities of Bimatoprost. Methylene blue may increase the hypertensive activities of Methylphenidate. Tromethamine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Clonidine. Methylphenidate may decrease the antihypertensive activities of Epoprostenol. The risk or severity of adverse effects can be increased when Ziprasidone is combined with Methylphenidate. The serum concentration of Fluindione can be increased when it is combined with Methylphenidate. The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole. Methylphenidate may increase the hypertensive activities of Sevoflurane. Methylphenidate may decrease the antihypertensive activities of Fenoldopam. The metabolism of Methylphenidate can be decreased when combined with Citalopram. Methylphenidate may decrease the antihypertensive activities of Rescinnamine.